Ann: Wilsons investor conference presentation, page-3

Further evidence in this presentation that the Dermatology Go to Market model is working and likely to be a big contributor to revenue and profit.

Epiduo (IQVIA $210 US) launched Feb 22- Market share 56%
Aczone (IQVIA $95 US) launched Feb 22. - Market share 31%
Absorica (IQVIA $140US) launched Sept 21 - Market share now 45% up from 39 in February update

Addionally,
Upsher-Smith , Mayne's Absorica partner, reported in May a 350% gain in revenue in dermatology due to Absorica.

Also 2 days ago Torrent, Mayne's Aczone partner made a small comment about an increase in US revenue aided by the launch of Dapsone (Aczone)